We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Sarossa | LSE:SARS | London | Ordinary Share | JE00BKWBZV64 | ORD 1P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 0.00 | 0.00% | 1.52 | 0.00 | 01:00:00 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| - |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| - | O | 0 | 1.52 | GBX |
Sarossa (SARS) Share Charts1 Year Sarossa Chart |
|
1 Month Sarossa Chart |
Intraday Sarossa Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 22/7/2020 | 12:41 | Severe Acute Respiratory Syndrome Epidemic (SARS) | 129 |
| 31/8/2016 | 20:00 | Sarossa Ld | 39 |
| 07/4/2009 | 08:09 | 2 MILLION people could die in the UK within a few months | 20 |
| 07/8/2005 | 11:42 | SARS - Who will produce the Vaccine | 38 |
| 17/12/2003 | 11:38 | SARS-WHO WILL PROFIT FROM IT? | 26 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|
| Top Posts |
|---|
Posted at 09/6/2020 13:03 by waldron source : Dow Jones NewsDanaher Unit Unveils Sars-CoV-2/Flu A/Flu B/RSV Combo Test Alert By Colin Kellaher Danaher Corp.'s Cepheid unit on Tuesday said it has developed a four-in-one test to detect Sars-CoV-2, Flu A, Flu B and respiratory syncytial virus from a single patient sample. The Sunnyvale, Calif., molecular-diagnostic Cepheid said the test will aid global efforts in the fight against Covid-19 during the upcoming respiratory virus season, as all four infections have similar patient presentations but different treatment and management pathways, making accurate detection and differentiation critical. Cepheid said it will pursue U.S. Food and Drug Administration approval of the test under the agency's emergency use authorization pathway. Write to Colin Kellaher at colin.kellaher@wsj.c (END) Dow Jones Newswires June 09, 2020 07:41 ET (11:41 GMT) |
Posted at 17/4/2020 16:05 by bunz3 even now to watch number of buyers moving back into ncyt after shsre price dropsome exspecting rns soon |
Posted at 01/7/2016 12:46 by charlie Have received circular re proposed acquisition of Ora Limited from (mainly) Richard Griffiths, Rule 9 waiver, tender offer buyback at 1.31p.Ora Limited is valued at £6.1m (full net asset value) Acquisition to be paid for by issuing Sarossa shares at 1.31p. This is half net asset value!! I think this is very poor price for independent shareholders. I will vote against. |
Posted at 19/11/2015 11:44 by johnsmith321 Hi Hlp_4U,I agree with you a revaluation is needed as SLN has halved in price since the last annual report. They bought £4M of SLN at 200p, then 300K at 240p. PHC is down 20%. GVC is also down. I think more than a £2M loss will be seen in the P+L unfortunately. I guess they may need to do more buybacks this years otherwise the NAV per share will be way down as well. GVC will go back to 450p once the overhang of people who do not like the merger/dividend holiday go. The same thing happened at Optimal payments. Once the merger is completed, it will lead to a improvement in price as will the move to the main market. How low (1.5p) are the BOD going to let Sarossa go before they do something. The original Sarossa cornerstone investors are way down. They need to bring in another cornerstone investor to hover up the overhang in shares otherwise this will continue down. In Adams plc, cornerston investors own 89.6%. I think they should have the same arrangement. |
Posted at 22/10/2015 16:05 by johnsmith321 David H Richardson, who was also a director and now major investor in Adam plc has now increased his stake here (4.04%). He clearly has a positive opinion of what can happen in a small investment company with 4 years of rising profits, EPS and NAV per share.Lets hope we see 2.4p soon. |
Posted at 16/10/2015 11:36 by johnsmith321 Hi guys,The largest shareholder Richard Griffiths acquired his stake in Sarossa at average price of about 2.4p in 2011 from my caculation. That puts his holding underwater. I am wondering why he has not forced the price up (by restricting stock) to at least break even level by now. At 2.4p any stock buybacks they want to do would still be at a big discount to NAV. Why do you think the stock price has stayed so low? |
Posted at 02/10/2015 11:50 by johnsmith321 SARS price ticking up to 1.8p. With only 100M shares. I agree that NAV is down at the moment, but I think PHC and SLN will go back up to 100p and 300p soon.No yield for GVC for the first year as with the last acquisition. The acquisition should stop GVC being dependent on any single source for more 10% earnings. In addition the move up to the main market should be positive for the share price. They also promised to maintain same rate of dividend once acquisition is completed. |
Posted at 29/9/2015 22:13 by callumross A good move, the cancellation of the prefs, John. NAV probably down a bit and just a little above 3p now due to PHC and SLN falling back a bit. Not so sure as you about GVC further investment John as no yield on GVC for a year to help pay for their big acquisition and they are subscribing at 422p which is a touch above current GVC price. Guess we'll just have to trust that they have got this investment decision right! |
Posted at 29/9/2015 19:39 by johnsmith321 Hi Callumross,Getting rid of the Abbvie pref shares made sense. As you say, they just cloud the investment picture. NAV up, investments up and profits up (if you exclude the one of Biotech legacy refund). Yet the share price has not moved. There must be a large share overhang. I do not care how they do it, but they should get the share price to 2p at least (as NAV per share is 3.35p). Perhaps they need to consolidate the shares 1:100 and get away from the penny share label. I like their follow on GVC investment (10% yield) should help to keep the NAV increasing year on year. |
Posted at 20/5/2015 16:29 by johnsmith321 Lets hope the next 48m shares does something to the share price :). They still have some cash. So they can continue buying back more shares. At some point the share price has to move. |
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
